Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 01 08 2018
revised: 24 10 2018
accepted: 16 11 2018
pubmed: 17 1 2019
medline: 2 11 2019
entrez: 17 1 2019
Statut: ppublish

Résumé

To assess the excess risk of HPV-associated cancer (HPVaC) in two at-risk groups-women with a previous diagnosis of high grade cervical intraepithelial neoplasia (CIN3) and both men and women treated for non-cervical pre-invasive anogenital disease. All CIN3 cases diagnosed in 1989-2015 in Scotland were extracted from the Scottish cancer registry (SMR06). All cases of pre-invasive penile, anal, vulval, and vaginal disease diagnosed in 1990-2015 were identified within the NHS pathology databases in the two largest NHS health boards in Scotland. Both were linked to SMR06 to extract subsequent incidence of HPVaC following the diagnosis of CIN3 or pre-invasive disease. Standardised incidence ratios were calculated for the risk of acquiring HPVaC for the two at-risk groups compared to the general Scottish population. Among 69,714 females in Scotland diagnosed with CIN3 (890,360.9 person-years), 179 developed non-cervical HPVaC. CIN3 cases were at 3.2-fold (95% CI: 2.7 to 3.7) increased risk of developing non-cervical HPVaC, compared to the general female population. Among 1,235 patients diagnosed with non-cervical pre-invasive disease (9,667.4 person-years), 47 developed HPVaC. Individuals with non-cervical pre-invasive disease had a substantially increased risk of developing HPVaC - 15.5-fold (95% CI: 11.1 to 21.1) increased risk for females and 28-fold (11.3 to 57.7) increased risk for males. We report a significant additional risk of HPV-associated cancer in those have been diagnosed with pre-invasive HPV-associated lesions including but not confined to the cervix. Uncovering the natural history of pre-invasive disease has potential for determining screening, prevention and treatment.

Identifiants

pubmed: 30650180
doi: 10.1002/ijc.32126
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-434

Subventions

Organisme : Chief Scientist Office
ID : CZH/4/528
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13063
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/3
Pays : United Kingdom

Informations de copyright

© 2019 UICC.

Auteurs

Jiafeng Pan (J)

Department of Mathematics and Statistics, University of Strathclyde, Glasgow, Scotland.

Kimberley Kavanagh (K)

Department of Mathematics and Statistics, University of Strathclyde, Glasgow, Scotland.
Information Services Division, NHS National Services Scotland, Edinburgh, Scotland.

Kate Cuschieri (K)

Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, Scotland.

Kevin G Pollock (KG)

Vaccine Preventable Diseases, Health Protection Scotland, Glasgow, Scotland.
School of Health & Life Sciences, Glasgow Caledonian University, Glasgow, Scotland.

Duncan C Gilbert (DC)

Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, Scotland.

David Millan (D)

Department of Pathology, the Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, Scotland.

Sarah Bell (S)

Department of Pathology, the Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, Scotland.

Sheila V Graham (SV)

MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, Scotland.

Alistair R W Williams (ARW)

Department of Pathology, University of Edinburgh, Edinburgh, Scotland.

Margaret E Cruickshank (ME)

Institute of Applied Health Sciences, University of Aberdeen, 2nd Floor, Aberdeen Maternity Hospital, Aberdeen, Scotland.

Tim Palmer (T)

Department of Pathology, University of Edinburgh, Edinburgh, Scotland.

Katie Wakeham (K)

Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, Scotland.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH